Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer
Authors:
- 31 January 2009
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 64 (4) , 673-680
Abstract
Combination of intravenous (i.v.) vinorelbine and capecitabine was shown to be feasible and effective in metastatic breast cancer (MBC). In an effort to improve patient convenience and to prolong infusion-free survival, we investigated in first-line treatment a regimen combining oral vinorelbine and capecitabine in a phase II study.Keywords
This publication has 22 references indexed in Scilit:
- Capecitabine: an overview of the side effects and their managementAnti-Cancer Drugs, 2008
- Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancerAnnals of Oncology, 2005
- Oral vinorelbine in metastatic breast cancer: Long-term results of 2 multicenter phase II studiesEuropean Journal of Cancer Supplements, 2004
- 801 Oral chemotherapy and upper gastro-intestinal tolerance (UGT) improvement of nausea and vomiting in non-small-cell-lung-cancer (NSCLC) patients (pts) treated with oral navelbine (NVB) and standard antiemetic prophylaxisEuropean Journal of Cancer Supplements, 2003
- Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumorsAnnals of Oncology, 2001
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997
- Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II studyBreast Cancer Research and Treatment, 1996
- Phase II Trial of Weekly IV Vinorelbine as a Single Agent in First-Line Advanced Breast Cancer ChemotherapyAmerican Journal of Clinical Oncology, 1995
- Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapyAnnals of Oncology, 1994
- A phase II, multicentre, UK study of vinorelbine in advanced breast cancerBritish Journal of Cancer, 1994